FILTER
LATEST ARTICLES
Shielding Africa From the Next Armageddon
June 17, 2020
Expert Opinion Article by Jerome Onoja, Managing Editor, Majorwaves Energy Report
Managing The Social Aspect
June 04, 2020
Social tensions must be eased to expedite project development in Peru.
Chile’s Copper Project Development
June 04, 2020
Increasing necessity for new projects today to meet tomorrow’s demand.
Building a Collaborative Mindset: The Key to Leveraging the Circular Economy and Creating a Sustainable Future, by Edison Terra (Braskem)
June 01, 2020
Expert Opinion Article by Edison Terra, Vice President of Olefins and Polyolefins at Braskem in South America.
Turkey’s Nascent Biopharma Sector: The Transition to Large Molecules
May 15, 2020
The Turkish pharma industry is on the eve of a rebirth as it seeks to grow a biopharma component.
Impact of COVID-19 in Turkey
May 14, 2020
Efforts to stave off the crisis are consequential in shaping future health and welfare policy.
Mining in the Shadow of COVID-19
May 12, 2020
Peru acts quickly as the COVID-19 pandemic devastates global economies.
Covid-19: Insights from Québec
May 12, 2020
The impact felt by the Exploration, Aviation and Natural Gas sectors in “La Belle Province”.
Nigeria and COVID-19: First-Hand Industry Insights
April 22, 2020
We ask four local experts about the real effects of the current crisis on their business and the wider oil and gas industry.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
United States Life Sciences 2023
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
